Sutro Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. on February 9, 2024. The filing addresses Item 8.01 (Other Events) regarding the company's equity financing arrangements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the company's equity offering capacity:
- Total Shares Sold to Date: $70,725,847.70 under the 2021 Form S-3 Shelf Registration Statement.
- Remaining Capacity (2021 Shelf): $29,274,152.30 available for sale as of the filing date.
- New Capacity (2023 Shelf Supplement): $100,000,000 added via a prospectus supplement filed on February 9, 2024.
- Total Available for Sale: Approximately $129,274,152.30 across both registration statements.
Material Changes
The primary material change is the expansion of the company's ability to raise capital through an "at-the-market" offering. On February 9, 2024, the company filed a prospectus supplement to its 2023 Form S-3 Shelf Registration Statement, increasing the aggregate dollar amount of shares available for sale by $100,000,000. This action follows the expiration of the 2021 shelf registration statement on April 2, 2024.
Outlook, Risks, and Management Commentary
The filing indicates the company's intent to continue utilizing the Open Market Sale Agreement with Jefferies LLC as the sales agent. No specific guidance on future revenue or operational milestones is provided in this document. The filing notes that the description of the Sales Agreement is qualified by reference to the full text of the agreement filed as Exhibit 1.1.
Key Facts for Investor Verification
- Verify the current share price and potential dilution impact of selling up to $129.3 million in shares.
- Confirm the expiration date of the 2021 Form S-3 Shelf Registration Statement (April 2, 2024).
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for commission rates and selling restrictions.
- Check subsequent filings for actual sales volumes executed under the new $100 million capacity.